Palbociclib treatment alters nucleotide biosynthesis and glutamine dependency in A549 cells.

ABSTRACT:

Background

Aberrant activity of cell cycle proteins is one of the key somatic events in non-small cell lung cancer (NSCLC) pathogenesis. In most NSCLC cases, the retinoblastoma protein tumor suppressor (RB) becomes inactivated via constitutive phosphorylation by cyclin dependent kinase (CDK) 4/6, leading to uncontrolled cell proliferation. Palbociclib, a small molecule inhibitor of CDK4/6, has shown anti-tumor activity in vitro and in vivo, with recent studies demonstrating a functional role for palbociclib in reprogramming cellular metabolism. While palbociclib has shown efficacy in preclinical models of NSCLC, the metabolic consequences of CDK4/6 inhibition in this context are largely unknown.

Methods

In our study, we used a combination of stable isotope resolved metabolom

SUBMITTER: Conroy LR 

PROVIDER: S-EPMC7329430 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature